← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

BRAF V600E Mutant Colorectal Cancer

MONDO:0005575 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 60 citations openscientist · 39 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

BRAF V600E-mutant colorectal cancer is driven by a somatic activating BRAF p.Val600Glu substitution that constitutively activates the RAS-RAF-MEK-ERK (MAPK/ERK) signaling cascade independent of upstream RAS or growth-factor stimuli, driving proliferation and apoptosis resistance.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% BRAF V600E acts downstream of EGFR and RAS to drive MAPK signaling, increasing proliferation and reducing apoptosis.
Falcon states the constitutive MAPK-driver mechanism and its proliferation/apoptosis outputs.
DOI:10.1158/1078-0432.CCR-19-3809
openscientist CONCORDANT 95% constitutive activation of the MAPK/ERK signaling pathway, independent of upstream RAS signaling or extracellular growth factor stimuli
OpenScientist gives the same driver mechanism and explicitly notes RAS- and ligand-independence of the constitutive MAPK/ERK activation.
PMID:39961465

BRAF V600E CRC arises predominantly through the serrated neoplasia pathway, an alternative route to carcinoma progressing through a hyperplasia/adenoma/carcinoma (sessile serrated lesion) sequence rather than the conventional APC-driven adenoma-carcinoma sequence.

MAJORITY INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% initiates an alternative pathway to colorectal cancer (CRC), which progresses through a hyperplasia/adenoma/carcinoma sequence
OpenScientist details the serrated-pathway progression from hyperplastic polyp through sessile serrated lesion to invasive carcinoma.
PMID:23845441
falcon PARTIAL 55% BRAF-mutant CRC is linked to CIMP biology (hypermethylation phenotype), often aligned with serrated pathway development.
Falcon links BRAF-mutant CRC to CIMP biology and serrated-pathway development but does not lay out the stepwise hyperplasia/adenoma/carcinoma serrated sequence. Partial: same pathway association, less mechanistic detail.
DOI:10.3390/cancers15215243

BRAF V600E CRC is epigenetically driven, exhibiting a high CpG island methylator phenotype (CIMP-high) with MLH1 promoter hypermethylation that silences mismatch repair and produces the MSI-H/dMMR subset (~50-60% of cases).

MAJORITY INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% is strongly associated with MLH1 DNA hypermethylation and the BRAF(V600E) mutation
OpenScientist ties CIMP-high directly to MLH1 hypermethylation and the BRAF V600E mutation, the epigenetic route to dMMR/MSI-H.
PMID:21659424
falcon PARTIAL 50% observed in 60% of MSI tumors vs 5–10% of MSS tumors
Falcon documents strong BRAF enrichment in sporadic MSI tumors and CIMP biology, but does not spell out the MLH1-promoter-methylation-to-dMMR mechanism. Partial: the MSI/CIMP association without the MLH1 silencing chain.
DOI:10.3390/cancers15215243

BRAF inhibitor monotherapy has limited activity in CRC because rapid EGFR-mediated feedback reactivation of MAPK signaling restores ERK activity; this rationale motivates combined BRAF plus EGFR (±MEK) blockade.

MAJORITY INTEGRATED
pathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling.
Falcon makes the EGFR-feedback reactivation the dominant mechanistic concept guiding combination therapy, citing BEACON CRC directly.
DOI:10.1056/NEJMoa1908075, DOI:10.1200/JCO.20.02088
openscientist PARTIAL 50% established the combination of encorafenib plus cetuximab (with or without binimetinib) as the standard of care for previously treated BRAF V600E-mutant metastatic CRC
OpenScientist endorses the combined BRAF+EGFR regimen as standard of care but does not articulate the EGFR-feedback reactivation mechanism explaining why BRAF monotherapy fails. Partial: supports the combination, silent on the rationale.
PMID:35653981

The BEACON CRC phase III trial established encorafenib plus cetuximab (with or without binimetinib) as standard of care for previously treated BRAF V600E-mutant mCRC, improving overall survival to 9.3 versus 5.9 months (HR ~0.60-0.61) over prior standard therapy.

UNANIMOUS INTEGRATED
treatmentprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% significantly improved overall survival (OS) compared with the previous standard of care
OpenScientist reports the BEACON regimen (9.3 vs 5.9 months; HR 0.60-0.61) as the definitive standard of care with the pivotal OS quote.
PMID:35653981
falcon CONCORDANT 95% Triplet: OS 9.3 mo, ORR 26.8%, grade≥3 AEs 65.8%; Doublet: OS 9.3 mo, ORR 19.5%, grade≥3 AEs 57.4%; Control: OS 5.9 mo, ORR 1.8%, grade≥3 AEs 64.2%
Falcon reports the updated BEACON survival results (9.3 vs 5.9 months) for both triplet and doublet arms with matching ORR and safety detail.
DOI:10.1200/JCO.20.02088

Acquired resistance to BRAF-targeted therapy is polyclonal and convergent, driven by MAPK-pathway reactivation through KRAS/RAS, MAP2K1, and MET alterations, with baseline TP53 mutation predisposing to acquired MET amplification.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factortreatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% Acquired resistance to BRAF-targeted therapy involves convergent MAPK reactivation through multiple genetic mechanisms including gene amplification of EGFR, KRAS, and mutant BRAF
OpenScientist describes convergent, polyclonal MAPK reactivation and the TP53-to-MET-amplification link.
PMID:27312529, PMID:39313594
falcon CONCORDANT 90% acquired alterations commonly involved RAS, MAP2K1, MET; baseline TP53 linked to acquired MET amplification
Falcon reports the same BEACON translational resistance findings (RAS/MAP2K1/MET; TP53-to-MET) and notes their subclonal/polyclonal nature.
DOI:10.1038/s41591-024-03235-9

BRAF V600E CRC has a distinctive clinicopathologic and epidemiologic profile: it accounts for roughly 8-15% of CRC and is enriched in right-sided/proximal tumors, female sex, older age, and mucinous/poorly differentiated histology with MSI-H features.

UNANIMOUS INTEGRATED
epidemiologyphenotype
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% strongly associated with right-sided tumors (55–69%), female sex (55–58%), older age, poorly differentiated/mucinous histology, MSI-H status, and CIMP-positive phenotype
OpenScientist gives quantified clinicopathologic enrichment and an 8-15% overall CRC frequency.
PMID:39538135, PMID:25005754, PMID:34249672
falcon CONCORDANT 75% BRAF V600E mCRC is also described as more often right-sided, more common in female patients, and associated with MSI-high features.
Falcon reports the same right-sided/female/MSI-high enrichment (with strong cohort odds ratios) but frames prevalence differently — 6.77% in a nationwide advanced-CRC cohort and ~10-15% in trial/review sources — a quantitative framing difference rather than a contradiction.
DOI:10.3390/ijms24109073

BRAF V600E is an adverse prognostic marker; the subtype is clinically aggressive with a poor prognosis and a median overall survival of approximately 14.9 months in the metastatic setting.

UNANIMOUS INTEGRATED
prognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% carrying a markedly poor prognosis, with a median overall survival (OS) of ~14.9 months in the metastatic setting
OpenScientist gives the ~14.9-month metastatic median OS and poor-prognosis framing.
PMID:39538135
falcon CONCORDANT 85% median OS 14.9 months; triplet chemotherapy+bevacizumab OS 17.4 vs 13.4 months
Falcon reports the same 14.9-month median OS from a multi-center real-world cohort, consistent with the poor-prognosis characterization.
DOI:10.1186/s12885-024-13171-z

The MSI-H/dMMR subset responds to immune checkpoint inhibitors, but BRAF V600E status within MSI-H CRC still confers worse outcomes than BRAF wild-type MSI-H tumors (median OS 19 vs 113 months; HR 2.69).

MAJORITY LEAD
treatmentprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% with median OS of 19 vs. 113 months
OpenScientist quantifies the worse outcome of BRAF V600E within the MSI-H population (HR 2.69; 19 vs 113 months) despite ICI eligibility.
PMID:39932790
falcon PARTIAL 45% MSI-H/dMMR status is a key selection biomarker for PD-1 blockade in metastatic CRC, including in BRAF-mutant disease.
Falcon agrees MSI-H/dMMR selects for checkpoint blockade in BRAF-mutant CRC but does not report the worse-than-BRAF-wild-type MSI-H outcome (19 vs 113 months). Partial: the immunotherapy-selection claim without the prognostic contrast.
DOI:10.1186/s12885-022-10420-x

Narrative

Overview

Both providers frame BRAF V600E-mutant colorectal cancer as a molecularly distinct, clinically aggressive CRC subtype driven by constitutive RAF-MEK-ERK (MAPK) signaling, associated with the serrated neoplasia pathway, CIMP-high methylation and MSI-H, and defined therapeutically by combined BRAF plus EGFR targeting (encorafenib plus cetuximab). Falcon is trial- and treatment-centric (60 citations, heavy on BEACON/ANCHOR/BREAKWATER outcomes and real-world cohorts); OpenScientist is broader and more mechanistic (39 citations, detailing serrated pathogenesis, epigenetics, resistance biology, and MSI-H prognosis).

Agreement

Both treat BRAF V600E CRC as an aggressive subtype driven by constitutive MAPK/ERK signaling with poor prognosis (median metastatic OS ~14.9 months). They agree that EGFR feedback reactivation undermines single-agent BRAF inhibition and supports combined BRAF plus EGFR targeting, that BEACON CRC established encorafenib plus cetuximab (±binimetinib) as standard of care (OS 9.3 vs 5.9 months), that acquired resistance is polyclonal and convergent on MAPK reactivation (KRAS/RAS, MAP2K1, MET; TP53 to MET amplification), and that the subtype is enriched in right-sided, female, older, mucinous/MSI-H tumors.

Divergence

Falcon emphasized targeted-therapy trial evidence, real-world encorafenib outcomes, and the treatment landscape, and it foregrounds the EGFR-feedback rationale for combination therapy. OpenScientist added a clearer serrated neoplasia model — CIMP-high with MLH1 promoter silencing, the MSI-H versus MSS split — and quantified the prognostic penalty of BRAF V600E within MSI-H CRC (19 vs 113 months). Quantitative framing of prevalence differs but does not conflict: Falcon cites 6.77% in a nationwide advanced-CRC cohort and ~10-15% across trials/reviews, OpenScientist cites 8-15% of all CRC. No direct contradictions were found.

Integration

Integrated into kb/disorders/BRAF_V600E_Mutant_Colorectal_Cancer.yaml: the serrated-neoplasia/CIMP-high and MLH1-silencing pathophysiology, the constitutive MAPK driver and EGFR-feedback reactivation rationale, acquired MAPK-reactivation resistance (KRAS/MAP2K1/MET; TP53 to MET), the BEACON encorafenib+cetuximab (±binimetinib) targeted-therapy standard, MSI-H/dMMR checkpoint-inhibitor coverage, the clinicopathologic enrichment profile, and the poor-prognosis natural history.

Not integrated (leads)

The precise BRAF-V600E-within-MSI-H prognostic contrast (19 vs 113 months) is retained as a research lead. Detailed investigational trial strategy (ANCHOR/BREAKWATER/SEAMARK), ctDNA-guided rechallenge and monitoring proposals, epigenetic-therapy hypotheses, first-line-optimization debates, and model-system limitations were left in research provenance as leads rather than promoted to curated disease mechanisms.

Two independent provider reports were compared: falcon (trial/treatment-focused) and openscientist (comprehensive, 15-domain). Neither report resolved a BRAF-V600E-specific MONDO subterm; both map the subtype to MONDO:0005575 (colorectal cancer), used here. Divergence is coverage/emphasis (OpenScientist adds serrated-pathway epigenetics and MSI-H prognosis; Falcon adds the EGFR-feedback treatment rationale and richer trial/real-world outcome data) plus a non-conflicting prevalence-framing difference. best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets were intentionally left unpopulated pending fetch-reference verification.